Medicare to negotiate prices for top drugs
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be ...
Medicare premiums and deductibles have increased for all retirees. There's now a $2,000 cap on annual out-of-pocket ...
The first openly trans member of Congress reflects on how her experience with love and loss taught her to pursue change from ...
As we step into 2025, the new year is a chance to embrace healthy living. For seniors and other Florida residents who are eligible for Medicare, key wellness goals start by making healthy decisions in ...
Monday’s Forbes Daily revisits Forbes’ best reporting on the incoming Trump Administration, including China’s meetings in D.C., advice for your investment portfolio and more.
During President Donald Trump's first term in office, the national debt increased by $8 trillion—due, in large part, to huge spending hikes that Congress passed and Trump signed.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback